Acadia (ACHC) Q2 2026 earnings review
Massive Free Cash Flow Reversal Overshadows Liability Noise
Acadia's headline numbers look disastrous at first glance: Reported Net Income collapsed 64% and Adjusted EBITDA plunged 26% YoY. However, these metrics are heavily distorted by a $28.6M professional liability (PLGL) reserve adjustment and the timing of state supplemental payments. Look under the hood and the operational pivot orchestrated by returning CEO Debbie Osteen is aggressively taking hold. CapEx was slashed by 77% YoY, transforming operating cash into explosive Free Cash Flow generation. Management raised FY26 guidance across the board (Revenue, EBITDA, EPS, and Cash Flow), signaling high confidence that the core business is accelerating despite the legacy liability anchors.
🐂 Bull Case
The era of unchecked expansion spending is over. Operating Cash Flow hit $162.1M (up 21% YoY) while CapEx dropped to $38.6M. The resulting free cash flow surge validates the strategic shift to capital discipline.
Management increased the midpoint of FY26 Revenue, Adjusted EBITDA, and Adjusted EPS guidance. Notably, Operating Cash Flow guidance was raised by $65M at the midpoint, an aggressive upward revision.
🐻 Bear Case
A $28.6M charge for 2025 Professional and General Liability (PLGL) claims crushed Q2 margins. Following Q4 2025's $52.7M hit, these recurring legacy liabilities are severely masking core profitability.
Specialty Treatment facility revenue decelerated further, dropping 8.4% YoY. The ongoing fallout from New York's out-of-state Medicaid restrictions continues to act as an anchor on the broader portfolio.
⚖️ Verdict: 🟢
Bullish. The 64% Net Income drop is an accounting distraction driven by non-cash reserve hikes and tough YoY payment comps. The 21% surge in Operating Cash Flow, 77% drop in CapEx, and sweeping guidance raises prove the core turnaround is accelerating.
Key Themes
Capital Discipline Delivers Immediate ROI
Acadia has firmly transitioned from aggressive capacity expansion to operational extraction. Q2 CapEx was heavily curtailed to $38.6M (down from $167.7M a year ago). This reversing trend generated massive free cash flow, allowing net leverage to stabilize. FY26 Operating Cash Flow guidance was raised by roughly 22% at the midpoint, proving the strategy is working rapidly.
PLGL Reserves: The Profitability Anchor
Adjusted EBITDA dropped 26% YoY to $149.2M, but the culprit is clear: a $28.6M charge related to 2025 professional and general liability (PLGL) claims. While management touts operational improvements, these retroactive legal/liability adjustments continue to act as a black box, creating a severe disconnect between healthy cash generation and depressed reported earnings.
Specialty Segment in Reversing Trend
The positive narrative of robust underlying demand is directly contradicted by the Specialty Treatment Facilities segment, where revenue decelerated by 8.4% YoY to $133.5M. This severe underperformance (compared to the company's +2.8% normalized growth) stems from facility closures and the lasting damage of New York's Medicaid policy blocking out-of-state transfers to Acadia's Pennsylvania facilities.
Residential and Acute Driving Core Volumes
Stripping away the noise of the Specialty segment, core demand is accelerating. Residential Treatment Facility revenue grew 12% YoY. Meanwhile, Acute Inpatient volumes (admissions) increased 5.5%, driven by the successful ramp-up of recently added beds and joint ventures, validating the previous years' capital investments.
State Payment Timing Distorts Run-Rates
Reported total revenue was flat (0%), but this is highly misleading. Q2 2025 contained a $48.7M out-of-period benefit from Tennessee, while Q2 2026 contained a $22.3M benefit from Florida. Normalizing for both, core total revenue is stable, growing 2.8%, and same-facility revenue is up 3.2%.
AI and Wearable Technology Integration
Management's strategy to combat rising PLGL claims and payer denials relies heavily on technology. The company continues piloting AI tools for risk prediction within its EMR systems and rolling out wearable safety devices for staff, tracking over 50 real-time KPIs to prove clinical outcomes to payers and reduce liability incidents.
Macro Risk: The OBBBA Legislation
The newly enacted 'One Big Beautiful Bill Act' (OBBBA) poses a credible macro threat. The legislation introduces work and community engagement requirements for the Medicaid expansion population and alters financing mechanisms. This could actively decelerate future admissions and pressure Acadia's heavy Medicaid book of business.
Other KPIs
Accelerating slightly. Patient days increased 0.8% YoY, reversing the narrative of declining Medicaid volumes seen in mid-2025. Total admissions increased 6.4% on a same-facility basis, indicating strong funnel velocity, though average length of stay compressed by 5.3% to 14.7 days.
Stable. Increased 4.8% YoY (4.4% on a same-facility basis). This growth rate is well aligned with normalized revenue growth and standard annual wage increases, suggesting the company has successfully eliminated the margin-crushing premium labor costs that plagued the industry in prior years.
Guidance
Stable. The lower end of the range was raised by $30M. The $3.425B midpoint implies roughly 3.4% YoY growth from FY25's $3.31B. This reflects confidence that Acute and Residential growth will easily offset the decay in the Specialty segment.
Stable. Range raised from the prior $580-$615M. The $602.5M midpoint implies a slight 1% deceleration from FY25's $608.9M, entirely driven by the ongoing absorption of heavy start-up losses for new facilities and the lingering PLGL reserve headwinds.
Accelerating dramatically. Guidance was aggressively raised from $285-$325M. At the $375M midpoint, this represents an explosive 184% increase over FY25's $131.9M. This is the ultimate proof point of the new management team's capital discipline mandate.
Decelerating. Cut from prior guidance of $255-$280M, and a massive reduction from the peak $571.8M spent in FY25. The company is actively choosing to harvest cash from its recent 2,500+ bed expansion cohort rather than pouring more capital into unproven ground-up builds.
Key Questions
Visibility into PLGL Reserves
You took a $28.6M hit for 2025 policy year claims this quarter, following a $52.7M adjustment in Q4. When do you expect these retroactive liability adjustments to definitively end, and what structural changes are preventing 2026 claims from repeating this pattern?
Specialty Segment Viability
With Specialty revenue down 8.4% and the New York Medicaid out-of-state restrictions seemingly permanent, what is the ultimate endgame for the affected Pennsylvania assets? Are divestitures on the table?
CapEx Floor vs Growth Targets
You've successfully slashed CapEx guidance to drive a massive free cash flow turnaround. How much lower can CapEx realistically go in 2027 before it begins to threaten your 400-600 annual bed addition target?
OBBBA Impact Mitigation
Given the passing of the OBBBA legislation and its Medicaid work requirements, what specific percentage of your current patient base is at risk of disenrollment, and how are you adapting your payer mix strategy?